North America Liver Disease Diagnostics Market By End User (Hospitals, Laboratories and Other End Users), By Diagnosis Technique (Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques), By Country, Industry Analysis and Forecast, 2020 - 2026
The North America Liver Disease Diagnostics Market would witness market growth of 5.8% CAGR during the forecast period (2020-2026).
Liver transplantation is the second most common organ transplant in the world after liver transplant. However, less than 10% of the global demands for organ transplantation are being met at the current rate of transplantation. While these numbers are sobering, they provide a significant incentive to improve public health, considering that most causes of liver disease are preventable.
The contrast agent, gadoxetic acid, is administered into a peripheral vein. It is absorbed by the liver cells (hepatocytes) and removed by the bile ducts. Chronic inflammation of the liver tissue, such as viral hepatitis or fatty liver disease, may lead to scarring (fibrosis/cirrhosis) of the organ, leading to a reduction in the number of functioning hepatocytes and/or a decrease in the number of cellular transporters responsible for the absorption of the contrast agent into hepatocytes. It ultimately leads to a decreased reduction of the liver as a contrast agent. Radiation-free fMRI shows damage to the liver cell as decreased liver light and impaired excretion of the contrast agent in the bile ducts by serial imaging.
North America dominated the market in the regional market. High investment in R&D and the involvement of key players are expected to be responsible for the growth of the liver disease diagnostics market in the region. In addition, the existence of organizations offering information on the treatment of diseases to patients is expected to drive the growth of the liver disease diagnostics industry. One such agency is GetPalliativeCare.org, which provides information on palliative care related to medical procedures such as endoscopy, CT scan, and biopsy.
Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited
Scope of the Study
Market Segmentation:
By End User
Liver transplantation is the second most common organ transplant in the world after liver transplant. However, less than 10% of the global demands for organ transplantation are being met at the current rate of transplantation. While these numbers are sobering, they provide a significant incentive to improve public health, considering that most causes of liver disease are preventable.
The contrast agent, gadoxetic acid, is administered into a peripheral vein. It is absorbed by the liver cells (hepatocytes) and removed by the bile ducts. Chronic inflammation of the liver tissue, such as viral hepatitis or fatty liver disease, may lead to scarring (fibrosis/cirrhosis) of the organ, leading to a reduction in the number of functioning hepatocytes and/or a decrease in the number of cellular transporters responsible for the absorption of the contrast agent into hepatocytes. It ultimately leads to a decreased reduction of the liver as a contrast agent. Radiation-free fMRI shows damage to the liver cell as decreased liver light and impaired excretion of the contrast agent in the bile ducts by serial imaging.
North America dominated the market in the regional market. High investment in R&D and the involvement of key players are expected to be responsible for the growth of the liver disease diagnostics market in the region. In addition, the existence of organizations offering information on the treatment of diseases to patients is expected to drive the growth of the liver disease diagnostics industry. One such agency is GetPalliativeCare.org, which provides information on palliative care related to medical procedures such as endoscopy, CT scan, and biopsy.
Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited
Scope of the Study
Market Segmentation:
By End User
- Hospitals, Laboratories and Other End Users
- Imaging
- Biopsy
- Endoscopy
- Laboratory tests and
- Other Diagnosis Techniques
- US
- Canada
- Mexico
- Rest of North America
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Boston Scientific Corporation
- Siemens AG (Siemens Healthineers)
- Bayer AG
- Merck & Co., Inc.
- Sanofi S.A.
- Novartis AG
- Pfizer, Inc.
- Randox laboratories limited
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Liver Disease Diagnostics Market, by End User
1.4.2 North America Liver Disease Diagnostics Market, by Diagnosis Technique
1.4.3 North America Liver Disease Diagnostics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY END USER
3.1 North America Hospitals Market by Country
3.2 North America Laboratories Market by Country
3.3 North America Other End Users Market by Country
CHAPTER 4. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE
4.1 North America Imaging Market by Country
4.2 North America Biopsy Market by Country
4.3 North America Endoscopy Market by Country
4.4 North America Laboratory tests Market by Country
4.5 North America Other Diagnosis Techniques Market by Country
CHAPTER 5. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY
5.1 US Liver Disease Diagnostics Market
5.1.1 US Liver Disease Diagnostics Market by End User
5.1.2 US Liver Disease Diagnostics Market by Diagnosis Technique
5.2 Canada Liver Disease Diagnostics Market
5.2.1 Canada Liver Disease Diagnostics Market by End User
5.2.2 Canada Liver Disease Diagnostics Market by Diagnosis Technique
5.3 Mexico Liver Disease Diagnostics Market
5.3.1 Mexico Liver Disease Diagnostics Market by End User
5.3.2 Mexico Liver Disease Diagnostics Market by Diagnosis Technique
5.4 Rest of North America Liver Disease Diagnostics Market
5.4.1 Rest of North America Liver Disease Diagnostics Market by End User
5.4.2 Rest of North America Liver Disease Diagnostics Market by Diagnosis Technique
CHAPTER 6. COMPANY PROFILES
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.1.5.3 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Approvals:
6.3 Boston Scientific Corporation
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Acquisition and Mergers:
6.4 Siemens AG (Siemens Healthineers)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Acquisition and Mergers:
6.4.5.3 Product Launches and Product Expansions:
6.5 Bayer AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Merck & Co., Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Randox Laboratories Limited
6.10.1 Company Overview
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Liver Disease Diagnostics Market, by End User
1.4.2 North America Liver Disease Diagnostics Market, by Diagnosis Technique
1.4.3 North America Liver Disease Diagnostics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY END USER
3.1 North America Hospitals Market by Country
3.2 North America Laboratories Market by Country
3.3 North America Other End Users Market by Country
CHAPTER 4. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE
4.1 North America Imaging Market by Country
4.2 North America Biopsy Market by Country
4.3 North America Endoscopy Market by Country
4.4 North America Laboratory tests Market by Country
4.5 North America Other Diagnosis Techniques Market by Country
CHAPTER 5. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY
5.1 US Liver Disease Diagnostics Market
5.1.1 US Liver Disease Diagnostics Market by End User
5.1.2 US Liver Disease Diagnostics Market by Diagnosis Technique
5.2 Canada Liver Disease Diagnostics Market
5.2.1 Canada Liver Disease Diagnostics Market by End User
5.2.2 Canada Liver Disease Diagnostics Market by Diagnosis Technique
5.3 Mexico Liver Disease Diagnostics Market
5.3.1 Mexico Liver Disease Diagnostics Market by End User
5.3.2 Mexico Liver Disease Diagnostics Market by Diagnosis Technique
5.4 Rest of North America Liver Disease Diagnostics Market
5.4.1 Rest of North America Liver Disease Diagnostics Market by End User
5.4.2 Rest of North America Liver Disease Diagnostics Market by Diagnosis Technique
CHAPTER 6. COMPANY PROFILES
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.1.5.3 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Approvals:
6.3 Boston Scientific Corporation
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Acquisition and Mergers:
6.4 Siemens AG (Siemens Healthineers)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Acquisition and Mergers:
6.4.5.3 Product Launches and Product Expansions:
6.5 Bayer AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Merck & Co., Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Randox Laboratories Limited
6.10.1 Company Overview
LIST OF TABLES
TABLE 1 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 2 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 3 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 4 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 5 NORTH AMERICA HOSPITALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 NORTH AMERICA HOSPITALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 NORTH AMERICA LABORATORIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 NORTH AMERICA LABORATORIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 NORTH AMERICA OTHER END USERS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 NORTH AMERICA OTHER END USERS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 12 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 13 NORTH AMERICA IMAGING MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 NORTH AMERICA IMAGING MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 NORTH AMERICA BIOPSY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 NORTH AMERICA BIOPSY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 NORTH AMERICA ENDOSCOPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 NORTH AMERICA ENDOSCOPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 NORTH AMERICA LABORATORY TESTS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 NORTH AMERICA LABORATORY TESTS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 NORTH AMERICA OTHER DIAGNOSIS TECHNIQUES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 NORTH AMERICA OTHER DIAGNOSIS TECHNIQUES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 24 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 25 US LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 26 US LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 27 US LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 28 US LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 29 US LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 30 US LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 31 CANADA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 32 CANADA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 33 CANADA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 34 CANADA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 35 CANADA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 36 CANADA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 37 MEXICO LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 38 MEXICO LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 39 MEXICO LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 40 MEXICO LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 41 MEXICO LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 42 MEXICO LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 43 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 44 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 45 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 46 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 47 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 48 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 49 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 50 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 51 KEY INFORMATION – BOSTON SCIENTIFIC CORPORATION
TABLE 52 KEY INFORMATION – SIEMENS AG
TABLE 53 KEY INFORMATION – BAYER AG
TABLE 54 KEY INFORMATION - MERCK & CO., INC.
TABLE 55 KEY INFORMATION – SANOFI S.A.
TABLE 56 KEY INFORMATION – NOVARTIS AG
TABLE 57 KEY INFORMATION – PFIZER, INC.
TABLE 58 KEY INFORMATION – RANDOX LABORATORIES LIMITED
TABLE 1 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 2 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 3 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 4 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 5 NORTH AMERICA HOSPITALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 NORTH AMERICA HOSPITALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 NORTH AMERICA LABORATORIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 NORTH AMERICA LABORATORIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 NORTH AMERICA OTHER END USERS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 NORTH AMERICA OTHER END USERS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 12 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 13 NORTH AMERICA IMAGING MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 NORTH AMERICA IMAGING MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 NORTH AMERICA BIOPSY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 NORTH AMERICA BIOPSY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 NORTH AMERICA ENDOSCOPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 NORTH AMERICA ENDOSCOPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 NORTH AMERICA LABORATORY TESTS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 NORTH AMERICA LABORATORY TESTS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 NORTH AMERICA OTHER DIAGNOSIS TECHNIQUES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 NORTH AMERICA OTHER DIAGNOSIS TECHNIQUES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 24 NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 25 US LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 26 US LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 27 US LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 28 US LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 29 US LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 30 US LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 31 CANADA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 32 CANADA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 33 CANADA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 34 CANADA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 35 CANADA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 36 CANADA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 37 MEXICO LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 38 MEXICO LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 39 MEXICO LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 40 MEXICO LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 41 MEXICO LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 42 MEXICO LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 43 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 44 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 45 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 46 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 47 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 48 REST OF NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 49 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 50 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 51 KEY INFORMATION – BOSTON SCIENTIFIC CORPORATION
TABLE 52 KEY INFORMATION – SIEMENS AG
TABLE 53 KEY INFORMATION – BAYER AG
TABLE 54 KEY INFORMATION - MERCK & CO., INC.
TABLE 55 KEY INFORMATION – SANOFI S.A.
TABLE 56 KEY INFORMATION – NOVARTIS AG
TABLE 57 KEY INFORMATION – PFIZER, INC.
TABLE 58 KEY INFORMATION – RANDOX LABORATORIES LIMITED
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 2 RECENT STRATEGIES AND DEVELOPMENTS: ABBOTT LABORATORIES
FIG 3 RECENT STRATEGIES AND DEVELOPMENTS: SIEMENS AG
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 2 RECENT STRATEGIES AND DEVELOPMENTS: ABBOTT LABORATORIES
FIG 3 RECENT STRATEGIES AND DEVELOPMENTS: SIEMENS AG
